The stream · Daily digest
The stream: Monday, October 5, 2026
6 briefs from ClinicalTrials.gov and FDA, grouped by desk. Each is two sentences from one primary source, linked to it.
Machine-summarized from primary sources; not independently reported. How we use automation
Clinical trials · 5
-
GL Pharm Tech Corporation registers Phase 3 trial of W2505 for erectile dysfunction
The study, first posted on ClinicalTrials.gov on October 5, 2026, plans to enroll 228 participants and begin in September 2026. It is a prospective, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of W2505.
Source: ClinicalTrials.gov registry record, October 5, 2026
-
Chiesi registers Phase 3 trial of CHF5993 vs Seretide in adolescent asthma
The study, first posted on ClinicalTrials.gov on October 5, 2026, plans to enroll 700 participants and start on November 16, 2026. It compares CHF5993 100/6/12.5 μg pMDI to Seretide Evohaler 125/25 μg pMDI over 52 weeks in adolescents with uncontrolled asthma.
Source: ClinicalTrials.gov registry record, October 5, 2026
-
Genmab registers Phase 3 trial of Rina-S in ovarian cancer
The study plans to enroll 602 participants and is expected to start in November 2026. It compares Rina-S alone or in combination with an approved standard of care treatment against the same available standard of care therapy by itself, or no treatment.
Source: ClinicalTrials.gov registry record, October 5, 2026
-
Incyte posts results of Phase 3 axatilimab trial in chronic graft-versus-host disease
Results for the Phase 3, open-label study of axatilimab in Japanese participants with recurrent or refractory active chronic graft-versus-host disease were first posted on ClinicalTrials.gov on October 5, 2026. The study enrolled 21 participants and completed primary data collection on August 6, 2025.
Source: ClinicalTrials.gov results record, October 5, 2026
-
Intra-Cellular Therapies, Inc. posts results of Lumateperone schizophrenia relapse study
The Phase 3 study enrolled 592 participants and was completed with primary completion on July 25, 2024. Results were first posted on ClinicalTrials.gov on October 5, 2026.
Source: ClinicalTrials.gov results record, October 5, 2026
Regulation · 1
-
FDA seeks public input to support ibogaine research
The FDA issued a request for information (RFI) to gather comments on early-phase clinical trial design for ibogaine drug products, including dose selection, safety monitoring and ethical oversight. Stakeholders have 45 days to submit comments, with the deadline on Friday, November 20, 2026.
Source: FDA press announcement, October 5, 2026